These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 36169649)

  • 81. Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study.
    Watanabe K; Yoh K; Hosomi Y; Usui K; Naka G; Kishi K; Uemura K; Ohashi Y; Kunitoh H
    BMJ Open; 2022 Jan; 12(1):e046451. PubMed ID: 34983748
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.
    Bae SY; Hong JY; Lee HJ; Park HJ; Lee SK
    Oncotarget; 2015 Apr; 6(12):10146-60. PubMed ID: 25760142
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib.
    Buder A; Hochmair MJ; Filipits M
    Target Oncol; 2021 Jan; 16(1):77-84. PubMed ID: 33270169
    [TBL] [Abstract][Full Text] [Related]  

  • 84. An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression.
    Safaric Tepes P; Pal D; Lindsted T; Ibarra I; Lujambio A; Jimenez Sabinina V; Senturk S; Miller M; Korimerla N; Huang J; Glassman L; Lee P; Zeltsman D; Hyman K; Esposito M; Hannon GJ; Sordella R
    Elife; 2021 Jul; 10():. PubMed ID: 34254585
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
    Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T
    Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).
    Fukui T; Sasaki J; Igawa S; Kada A; Saito TI; Kogure Y; Okamoto H; Naoki K
    BMC Cancer; 2022 Dec; 22(1):1314. PubMed ID: 36522630
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
    Wang X; Cai J; Zeng Z; Liu A
    BMC Cancer; 2021 Jul; 21(1):873. PubMed ID: 34330231
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.
    Lin YT; Tsai TH; Wu SG; Liu YN; Yu CJ; Shih JY
    Lung Cancer; 2020 Jul; 145():1-9. PubMed ID: 32387812
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.
    Yang Z; Yang N; Ou Q; Xiang Y; Jiang T; Wu X; Bao H; Tong X; Wang X; Shao YW; Liu Y; Wang Y; Zhou C
    Clin Cancer Res; 2018 Jul; 24(13):3097-3107. PubMed ID: 29506987
    [No Abstract]   [Full Text] [Related]  

  • 90. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
    Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
    Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion.
    Nokihara H; Ogino H; Mitsuhashi A; Kondo K; Ogawa E; Ozaki R; Yabuki Y; Yoneda H; Otsuka K; Nishioka Y
    BMC Cancer; 2022 Jun; 22(1):597. PubMed ID: 35650550
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

  • 96. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.
    Ghiso E; Migliore C; Ciciriello V; Morando E; Petrelli A; Corso S; De Luca E; Gatti G; Volante M; Giordano S
    Neoplasia; 2017 Dec; 19(12):1012-1021. PubMed ID: 29136529
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
    Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A
    Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status.
    Liao J; Huang Y; Gan J; Pang L; Ali WAS; Yang Y; Chen L; Zhang L; Fang W
    Cancer Control; 2022; 29():10732748221081360. PubMed ID: 35201951
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
    Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC.
    Kunimasa K; Nishino K; Sato Y; Mori M; Ihara S; Suzuki H; Nagatomo I; Kumagai T; Morishima T; Imamura F
    Sci Rep; 2022 Aug; 12(1):13544. PubMed ID: 35941190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.